Head to Head Comparison: Abivax (NASDAQ:ABVX) and Forte Biosciences (NASDAQ:FBRX)

Abivax (NASDAQ:ABVX) and Forte Biosciences (NASDAQ:FBRX) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, analyst recommendations, risk, institutional ownership and dividends.

Analyst Ratings

This is a summary of recent ratings and price targets for Abivax and Forte Biosciences, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1	1	14	0	2.81
Forte Biosciences	1	0	3	0	2.50

Abivax currently has a consensus target price of $144.46, indicating a potential upside of 8.37%. Forte Biosciences has a consensus target price of $67.00, indicating a potential upside of 215.52%. Given Forte Biosciences’ higher probable upside, analysts plainly believe Forte Biosciences is more favorable than Abivax.

Insider and Institutional Ownership

47.9% of Abivax shares are owned by institutional investors. Comparatively, 77.6% of Forte Biosciences shares are owned by institutional investors. 4.4% of Forte Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Abivax and Forte Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-99.02%	-70.26%
Forte Biosciences	N/A	-106.17%	-85.50%

Volatility & Risk

Abivax has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500. Comparatively, Forte Biosciences has a beta of 2.87, meaning that its share price is 187% more volatile than the S&P 500.

Earnings and Valuation

This table compares Abivax and Forte Biosciences”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27 million	($5.21)	-25.59
Forte Biosciences	N/A	N/A	-$69.38 million	($4.64)	-4.58

Abivax is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks.

Summary

Forte Biosciences beats Abivax on 7 of the 11 factors compared between the two stocks.

About Abivax

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

About Forte Biosciences

Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.